Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Yinkai Duan, Hao Zhou, Xiang Liu, et al.
Nature (2023) Vol. 622, Iss. 7982, pp. 376-382
Closed Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Long COVID science, research and policy
Ziyad Al‐Aly, Hannah Davis, Lisa McCorkell, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2148-2164
Open Access | Times Cited: 109
Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections
Mohammed Nooruzzaman, Katherine Johnson, Ruchi Rani, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 13
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Lijing Zhang, Xuping Xie, Hannan Luo, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 13
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 10
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 10
Contributions of Hyperactive Mutations in Mpro from SARS-CoV-2 to Drug Resistance
Julia M. Flynn, Sarah N. Zvornicanin, Tenzin Tsepal, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 4, pp. 1174-1184
Closed Access | Times Cited: 9
Proof-of-concept studies with a computationally designed M pro inhibitor as a synergistic combination regimen alternative to Paxlovid
Christina Papini, Irfan Ullah, Amalendu P. Ranjan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 17
Open Access | Times Cited: 9
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 9
Repurposing Drugs for Synergistic Combination Therapies to Counteract Monkeypox Virus Tecovirimat Resistance
Haydar Witwit, Beatrice Cubitt, Roaa Khafaji, et al.
Viruses (2025) Vol. 17, Iss. 1, pp. 92-92
Open Access | Times Cited: 1
Distal protein-protein interactions contribute to nirmatrelvir resistance
Eric M. Lewandowski, Xiujun Zhang, Haozhou Tan, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access | Times Cited: 1
Synthesis and evolution of 16-membered macrolide carrimycin derivatives as a novel class of anti-HCoV-OC43 agents targeting viral FSE RNA
Xiuli Zhong, Zhihui Yu, Runze Meng, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117373-117373
Closed Access | Times Cited: 1
Systematic Reevaluation of Repurposed Drugs Against the Main Protease of SARS‐CoV‐2 via Combined Experiments
Jialu Ye, Rui Zhang, Jiahao Zhou, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 2
Closed Access | Times Cited: 1
A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein
Ellen Van Damme, Pravien Abeywickrema, Yanting Yin, et al.
Nature (2025)
Open Access | Times Cited: 1
Discovery of SARS-CoV-2 papain-like protease (PL pro ) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, et al.
Science Advances (2024) Vol. 10, Iss. 35
Open Access | Times Cited: 7
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy
Yufei Xiang, Jialu Xu, Briana L. McGovern, et al.
Cell (2024)
Closed Access | Times Cited: 7
The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2
Yuan Hu, Lili Liu, Shenghua Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 5, pp. 5175-5192
Open Access | Times Cited: 6
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 6
Computational evaluation and benchmark study of 342 crystallographic holo-structures of SARS-CoV-2 Mpro enzyme
Hamlet Khachatryan, Mher Matevosyan, Vardan Harutyunyan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 6
Exploring the structural and molecular interaction landscape of nirmatrelvir and Mpro complex: The study might assist in designing more potent antivirals targeting SARS-CoV-2 and other viruses
Chiranjib Chakraborty, Manojit Bhattacharya, Abdulrahman Alshammari, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 12, pp. 1961-1970
Open Access | Times Cited: 14
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
Michelle R. Garnsey, Matthew C. Robinson, Luong T. Nguyen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Resistance‐associated mutations to the anti‐SARS‐CoV‐2 agent nirmatrelvir: Selection not induction
Philippe Colson, Jérémy Delerce, Pierre Pontarotti, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 4
Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system
Stefanie Rauch, Francesco Costacurta, Helge Schöppe, et al.
Antiviral Research (2024) Vol. 231, pp. 105969-105969
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top